Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis-Reference-Cited by-同舟云学术

Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis

Published:2021-06-03 Issue:6 Volume:15 Page:813-823
ISSN:1750-2640
Container-title:Influenza and Other Respiratory Viruses
language:en
Short-container-title:Influenza Resp Viruses

Author:

Coleman Brenda L.¹²³^ORCID,Sanderson Ruth¹,Haag Mendel D. M.⁴,McGovern Ian⁵

Affiliation:

1. Sinai Health Toronto ON Canada

2. Dalla Lana School of Public Health Toronto ON Canada

3. Western University London ON Canada

4. Seqirus Netherlands B.V Amsterdam the Netherlands

5. Seqirus Inc Cambridge MA USA

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.12871

Reference53 articles.

1. Complications of Viral Influenza

2. Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993–2008

3. Complicated hospitalization due to influenza: results from the Global Hospital Influenza Network for the 2017–2018 season

4. Estimates of deaths associated with seasonal influenza – United States, 1976–2007;Centres for Disease Control and Prevention;MMWR Morb Mortal Wkly Rep,2010

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relative vaccine effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017–2020 influenza seasons;International Journal of Infectious Diseases;2024-09

2. Relative Effectiveness of the MF59-Adjuvanted Influenza Vaccine Versus High-Dose Influenza Vaccine in Older Adults With Influenza Risk Factors During the 2019–2020 US Influenza Season;Open Forum Infectious Diseases;2024-07-30

3. Mapping and ranking outcomes for the evaluation of seasonal influenza vaccine efficacy and effectiveness: a delphi study;Expert Review of Vaccines;2024-06-25

4. The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses;Human Vaccines & Immunotherapeutics;2024-06-04

5. Vaccines against extraintestinal pathogenic Escherichia coli (ExPEC): progress and challenges;Gut Microbes;2024-06-02